Literature DB >> 7540855

Expansion of CD8+CD57+ T cells after allogeneic BMT is related with a low incidence of relapse and with cytomegalovirus infection.

H Dolstra1, F Preijers, E Van de Wiel-van Kemenade, A Schattenberg, J Galama, T de Witte.   

Abstract

Peripheral blood lymphocytes of 46 recipients of lymphocyte-depleted bone marrow allografts were phenotypically analysed over a period of 1 year. We investigated the repopulation of lymphocyte subpopulations and their relation with clinical parameters such as graft-versus-host disease (GVHD), graft-versus-leukaemia and cytomegalovirus (CMV) infection. The number of repopulated T cells varied strongly between the blood samples of the recipients. In 45% of the recipients the number of T cells recovered to or above normal levels within 3 months after bone marrow transplantation (BMT), whereas the other recipients remained below normal up to 1 year after BMT. In recipients with a high repopulation, the CD8+ T-cell subset contributed more to this high repopulation than the CD4+ T-cell subset. We showed that the majority of T cells of these recipients expressed the alpha beta T-cell receptor, CD8, CD57 and CD11b. HLA-DR was also highly expressed reflecting the activation stage of T cells in these recipients. BMT recipients with a high repopulation of CD8+ T cells showed a lower incidence of leukaemic relapse than recipients with a low repopulation. The 3-year probability of relapse was 19% versus 64% (P = 0.03), respectively. The relative high number of CD8+ T cells at 3 months after BMT was not associated with the incidence of GVHD. In contrast, occurrence of CMV infection after BMT was significantly higher in these recipients. Our results indicate that CD8+ T cells, predominantly CD57+, of BMT recipients with an expansion of these cells represent an in vivo activated cell population. This CD8+ T-cell population may consist partially of cytotoxic cells with anti-leukaemic activity as suggested by a low relapse rate. The signal for the strong expansion of these CD8+CD57+ T cells after BMT is still unclear, but association with CMV infection suggests that viral antigens are involved.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540855     DOI: 10.1111/j.1365-2141.1995.tb05150.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  15 in total

1.  Detection and characterization of a novel subset of CD8⁺CD57⁺ T cells in metastatic melanoma with an incompletely differentiated phenotype.

Authors:  Richard C Wu; Shujuan Liu; Jessica A Chacon; Sheng Wu; Yufeng Li; Pariya Sukhumalchandra; James L Murray; Jeffrey J Molldrem; Patrick Hwu; Hanspeter Pircher; Gregory Lizée; Laszlo G Radvanyi
Journal:  Clin Cancer Res       Date:  2012-02-03       Impact factor: 12.531

2.  Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity.

Authors:  Mohammad S Hossain; David L Jaye; Brian P Pollack; Alton B Farris; Malefa L Tselanyane; Ebenezer David; John D Roback; Andrew T Gewirtz; Edmund K Waller
Journal:  J Immunol       Date:  2011-10-17       Impact factor: 5.422

Review 3.  The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Miriam Ciáurriz; Amaya Zabalza; Lorea Beloki; Cristina Mansilla; Estela Pérez-Valderrama; Mercedes Lachén; Eva Bandrés; Eduardo Olavarría; Natalia Ramírez
Journal:  Cell Mol Life Sci       Date:  2015-07-15       Impact factor: 9.261

Review 4.  CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease.

Authors:  Marius Strioga; Vita Pasukoniene; Dainius Characiejus
Journal:  Immunology       Date:  2011-06-29       Impact factor: 7.397

5.  Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation.

Authors:  Zaid Al-Kadhimi; Zartash Gul; Roberto Rodriguez; Wei Chen; Daryn Smith; Alice Mitchell; Muneer Abidi; Lois Ayash; Abhinav Deol; Lawrence Lum; Stephen Forman; Voravit Ratanatharathorn; Joseph Uberti
Journal:  Biol Blood Marrow Transplant       Date:  2012-06-16       Impact factor: 5.742

6.  Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy.

Authors:  Zinaida Good; Jay Y Spiegel; Bita Sahaf; Meena B Malipatlolla; Zach J Ehlinger; Sreevidya Kurra; Moksha H Desai; Warren D Reynolds; Anita Wong Lin; Panayiotis Vandris; Fang Wu; Snehit Prabhu; Mark P Hamilton; John S Tamaresis; Paul J Hanson; Shabnum Patel; Steven A Feldman; Matthew J Frank; John H Baird; Lori Muffly; Gursharan K Claire; Juliana Craig; Katherine A Kong; Dhananjay Wagh; John Coller; Sean C Bendall; Robert J Tibshirani; Sylvia K Plevritis; David B Miklos; Crystal L Mackall
Journal:  Nat Med       Date:  2022-09-12       Impact factor: 87.241

7.  Inverse relationship between oligoclonal expanded CD69- TTE and CD69+ TTE cells in bone marrow of multiple myeloma patients.

Authors:  Slavica Vuckovic; Christian E Bryant; Ka Hei Aleks Lau; Shihong Yang; James Favaloro; Helen M McGuire; Georgina Clark; Barbara Fazekas de St Groth; Felix Marsh-Wakefield; Najah Nassif; Edward Abadir; Vinay Vanguru; Derek McCulloch; Christina Brown; Stephen Larsen; Scott Dunkley; Liane Khoo; John Gibson; Richard Boyle; Douglas Joshua; P Joy Ho
Journal:  Blood Adv       Date:  2020-10-13

8.  Impact of cytomegalovirus and grafts versus host disease on the dynamics of CD57+CD28-CD8+ T cells after bone marrow transplant.

Authors:  Ana Verena Almeida Mendes; Esper Georges Kallas; Gil Benard; Cláudio Sérgio Pannuti; Reneé Menezes; Frederico Luiz Dulley; Thomas George Evans; Reinaldo Salomão; Clarisse Martins Machado
Journal:  Clinics (Sao Paulo)       Date:  2008-10       Impact factor: 2.365

Review 9.  Dysregulation of CD8+ lymphocyte apoptosis, chronic disease, and immune regulation.

Authors:  Karen L Wood; Homer L Twigg; Andrea I Doseff
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

Review 10.  Functional Significance of CD57 Expression on Human NK Cells and Relevance to Disease.

Authors:  Carolyn M Nielsen; Matthew J White; Martin R Goodier; Eleanor M Riley
Journal:  Front Immunol       Date:  2013-12-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.